“Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors” (2015) Journal of Analytical Oncology, 4(3), pp.  94–101. doi:10.6000/1927-7229.2015.04.03.1.